IL281979B2 - Human antibodies that bind amyloid peptides - Google Patents

Human antibodies that bind amyloid peptides

Info

Publication number
IL281979B2
IL281979B2 IL281979A IL28197921A IL281979B2 IL 281979 B2 IL281979 B2 IL 281979B2 IL 281979 A IL281979 A IL 281979A IL 28197921 A IL28197921 A IL 28197921A IL 281979 B2 IL281979 B2 IL 281979B2
Authority
IL
Israel
Prior art keywords
antibody
seq
nt4x
domain
antibodies
Prior art date
Application number
IL281979A
Other languages
English (en)
Hebrew (he)
Other versions
IL281979B1 (en
IL281979A (en
Inventor
Thomas Bayer
Preeti Bakrania
Sarah Davies
Alex Brown
Chido Mpamhanga
David Matthews
Mark Carr
Gareth Hall
Original Assignee
Georg August Universit?T G?Ttingen Stiftung ?Ffentlichen Rechts Universit?Tsmedizin
Lifearc
Thomas Bayer
Preeti Bakrania
Sarah Davies
Alex Brown
Chido Mpamhanga
David Matthews
Mark Carr
Gareth Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg August Universit?T G?Ttingen Stiftung ?Ffentlichen Rechts Universit?Tsmedizin, Lifearc, Thomas Bayer, Preeti Bakrania, Sarah Davies, Alex Brown, Chido Mpamhanga, David Matthews, Mark Carr, Gareth Hall filed Critical Georg August Universit?T G?Ttingen Stiftung ?Ffentlichen Rechts Universit?Tsmedizin
Publication of IL281979A publication Critical patent/IL281979A/en
Publication of IL281979B1 publication Critical patent/IL281979B1/en
Publication of IL281979B2 publication Critical patent/IL281979B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL281979A 2018-10-04 2019-10-02 Human antibodies that bind amyloid peptides IL281979B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201816210 2018-10-04
PCT/EP2019/076772 WO2020070225A1 (en) 2018-10-04 2019-10-02 Humanised anti-n-truncated amyloid beta monoclonal antibody

Publications (3)

Publication Number Publication Date
IL281979A IL281979A (en) 2021-05-31
IL281979B1 IL281979B1 (en) 2025-05-01
IL281979B2 true IL281979B2 (en) 2025-09-01

Family

ID=68136417

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281979A IL281979B2 (en) 2018-10-04 2019-10-02 Human antibodies that bind amyloid peptides

Country Status (13)

Country Link
US (1) US12297261B2 (https=)
EP (1) EP3861023A1 (https=)
JP (1) JP7610515B2 (https=)
KR (1) KR102862077B1 (https=)
CN (1) CN113056480B (https=)
AU (1) AU2019354714A1 (https=)
BR (1) BR112021006153A2 (https=)
CA (1) CA3114669A1 (https=)
EA (1) EA202190954A1 (https=)
IL (1) IL281979B2 (https=)
MX (1) MX2021003867A (https=)
SG (1) SG11202102765RA (https=)
WO (1) WO2020070225A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4118111A1 (en) 2020-03-10 2023-01-18 LifeArc Cyclic peptides
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167681A1 (en) * 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
US8795664B2 (en) * 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2017009459A2 (en) * 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474900A (en) 1892-05-17 William byrnes
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO2008081008A1 (en) * 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
MY155144A (en) 2007-10-29 2015-09-15 Inst Nat Sante Rech Med NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
WO2015173133A1 (en) 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP4118111A1 (en) * 2020-03-10 2023-01-18 LifeArc Cyclic peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795664B2 (en) * 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2013167681A1 (en) * 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
WO2017009459A2 (en) * 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTONIOS, GREGORY, ET AL., ALZHEIMER THERAPY WITH AN ANTIBODY AGAINST N-TERMINAL ABETA 4-X AND PYROGLUTAMATE ABETA 3-X., 31 December 2015 (2015-12-31) *
ANTONIOS, GREGORY, ET AL., N-TRUNCATED ABETA STARTING WITH POSITION FOUR: EARLY INTRANEURONAL ACCUMULATION AND RESCUE OF TOXICITY USING NT4X-167, A NOVEL MONOCLONAL ANTIBODY., 31 December 2013 (2013-12-31) *
BOUTER, YVONNE, ET AL., ABETA TARGETS OF THE BIOSIMILAR ANTIBODIES OF BAPINEUZUMAB, CRENEZUMAB, SOLANEZUMAB IN COMPARISON TO AN ANTIBODY AGAINST N-TRUNCATED ABETA IN SPORADIC ALZHEIMER DISEASE CASES AND MOUSE MODELS., 31 December 2015 (2015-12-31) *

Also Published As

Publication number Publication date
CA3114669A1 (en) 2020-04-09
JP7610515B2 (ja) 2025-01-08
BR112021006153A2 (pt) 2021-06-29
MX2021003867A (es) 2021-09-08
JP2022513331A (ja) 2022-02-07
EA202190954A1 (ru) 2021-06-29
US20210347867A1 (en) 2021-11-11
EP3861023A1 (en) 2021-08-11
CN113056480A (zh) 2021-06-29
AU2019354714A1 (en) 2021-04-29
SG11202102765RA (en) 2021-04-29
KR102862077B1 (ko) 2025-09-18
KR20210080400A (ko) 2021-06-30
US12297261B2 (en) 2025-05-13
IL281979B1 (en) 2025-05-01
IL281979A (en) 2021-05-31
CN113056480B (zh) 2025-06-13
US20230203140A9 (en) 2023-06-29
WO2020070225A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US12297261B2 (en) Humanised anti-n-truncated amyloid β monoclonal antibody
CN101687031B (zh) 用于治疗眼疾和眼病的组合物及方法
KR102431830B1 (ko) 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
RU2771384C2 (ru) Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение
WO2019062832A1 (zh) Tigit抗体、其抗原结合片段及医药用途
JP2020124203A (ja) 血液脳関門輸送分子およびそれらの使用
KR20120075457A (ko) 톨-유사 수용체 2에 대한 인간화 항체 및 이의 용도
BRPI0806340A2 (pt) anticorpos de sp35 e usos dos mesmos
BR112019025048A2 (pt) anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos
JP2025041747A (ja) ヒト化抗ｉｌ１７ｂｒ抗体
TW201813979A (zh) 抗ｃｄ２７抗體、其抗原結合片段及其醫藥用途
WO2021190582A1 (zh) 一种抗ox40抗体药物组合物及其用途
AU2019394099B2 (en) Humanised anti-IL17BR antibody
RU2830101C1 (ru) Антитело к angptl3 и его применение
US20230227541A1 (en) Anti-myocilin olf antibodies and methods of use thereof
WO2026012421A1 (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
HK40128682A (zh) 结合c1s的抗体和其用途
NZ622092A (en) Antibodies against tl1a and uses thereof
HK1236204A1 (en) Anti-transferrin receptor antibodies and methods of use
HK1142613A (en) Methods of treating ophthalmic diseases
HK1142613B (en) Methods of treating ophthalmic diseases
NZ622092B2 (en) Antibodies against tl1a and uses thereof